However, a lot of studies using 6-OHDA model given an inhibitor of NAT as a pretreatment, in order to protect noradrenergic terminal from 6-OHDA toxicity, precluding the possibility of PD symptomatology analysis as observed in PD patients. This evidence concerns the gene BRD2 and Parkinson disease.